

Edgar Filing: H&Q HEALTHCARE INVESTORS - Form 13F-HR

H&Q HEALTHCARE INVESTORS
 Form 13F-HR
 May 02, 2001

FORM 13F

 (SEC USE ONLY)

Name of Reporting Manager:
 HAMBRECHT & QUIST CAPITAL MANAGEMENT

| Item 1: Name of Issuer ----- | Item 2: Title of Class ----- | Item 3: CUSIP Number ----- | Item 4: Fair Market Value ----- | Item 5: Shares Principal Amount ----- |
|------------------------------------|------------------------------------|-------------------------------------|--|--|
| Affymetrix | Common | 00826T108 | 2,781,250 | 10 |
| Aradigm | Common | 038505103 | 2,012,500 | 35 |
| ATS Medical | Common | 002083103 | 6,125,003 | 63 |
| Biofield | Common | 090591207 | 325,143 | 87 |
| Biofield (Restricted) | Common | 090591207 | 296,000 | 1,00 |
| Bioject Medical Technologies | Common | 09059T206 | 2,603,125 | 23 |
| Biopure | Common | 09065H915 | 2,259,744 | 16 |
| BioTransplant | Common | 09066Y107 | 3,785,252 | 71 |
| Biovail | Common | 09067K106 | 33,288,303 | 92 |
| Calypte Biomedical | Common | 131722100 | 700,156 | 1,09 |
| Catalytica Energy Systems | Common | 148884109 | 2,690,783 | 12 |
| Celgene | Common | 151020104 | 17,250,000 | 69 |
| Cor Therapeutics | Common | 217753102 | 6,750,000 | 30 |
| Corixa | Common | 21887F100 | 3,131,680 | 39 |
| Cubist Pharmaceuticals | Common | 229990981 | 23,471,123 | 95 |
| Curis | Common | 231269101 | 1,261,592 | 34 |
| CV Therapeutics | Common | 126667104 | 18,028,131 | 54 |
| Cytc | Common | 232946103 | 7,165,719 | 43 |
| Digene | Common | 253752109 | 3,507,500 | 23 |
| Dyax | Common | 26746E103 | 4,374,120 | 54 |
| Emisphere Technologies | Common | 291345106 | 2,161,188 | 15 |
| Endocardial Solutions (Restricted) | Common | 292962107 | 5,624,998 | 1,66 |
| Envirogen | Common | 294040100 | 22,135 | 2 |
| EP Med Systems | Common | 26881P103 | 2,418,750 | 1,07 |
| Exelixis | Common | 30161Q104 | 1,946,000 | 22 |
| Focal | Common | 343909107 | 169,985 | 27 |
| Genzyme | Common | 372917104 | 17,388,525 | 19 |
| Genzyme Biosurgery | Common | 372917708 | 635,508 | 11 |
| Gilead Sciences | Common | 37555B103 | 23,182,835 | 35 |
| IDEXX Laboratories | Common | 45168D104 | 5,484,375 | 25 |
| ImClone Systems | Common | 45245W109 | 18,087,188 | 54 |
| Interpore Cross | Common | 46062W107 | 1,579,106 | 37 |
| KeraVision | Common | 648990992 | 11,340 | 20 |
| Landec | Common | 514766104 | 1,908,534 | 52 |
| Lynx Therapeutics | Common | 551812308 | 3,518,203 | 37 |
| Martek Biosciences | Common | 572901106 | 12,093,473 | 78 |
| MedImmune | Common | 584699102 | 11,838,750 | 33 |
| Molecular Devices | Common | 60851C107 | 13,229,945 | 29 |

Edgar Filing: H&Q HEALTHCARE INVESTORS - Form 13F-HR

| | | | | |
|--------------------------------|--------|-----------|-------------|------|
| Orthovita (Restricted) | Common | 68750U102 | 10,040,710 | 1,70 |
| Quintiles Transnational | Common | 748767100 | 2,885,988 | 15 |
| Radiance Medical Systems | Common | 750241101 | 1,185,938 | 33 |
| Scios | Common | 808905103 | 12,822,500 | 55 |
| Sepracor | Common | 817315104 | 11,428,416 | 35 |
| Telik | Common | 87959M109 | 3,458,324 | 66 |
| Teva Pharmaceutical Industries | Common | 881624209 | 5,462,500 | 10 |
| Transkaryotic Therapies | Common | 893735100 | 6,718,534 | 38 |
| Tularik | Common | 899165104 | 7,702,695 | 40 |
| Verdant Brands | Common | 923366108 | 950 | 3 |
| Versicor | Common | 925314106 | 6,046,875 | 75 |
| Versicor (Restricted) | Common | 925314106 | 1,795,573 | 29 |
| COLUMN TOTALS | | | 332,656,965 | |

Item 6:
Investment Discretion

| | (a) Sole | (b) Shared- As Defined in Instr. V | (c) Shared- Other | Item 7: Managers See Instr. V | V ----- (a) S |
|------------------------------------|----------|--|----------------------|-------------------------------------|---------------------|
| Affymetrix | X | | | NA | |
| Aradigm | X | | | NA | |
| ATS Medical | X | | | NA | |
| Biofield | X | | | NA | |
| Biofield (Restricted) | X | | | NA | |
| Bioject Medical Technologies | X | | | NA | |
| Biopure | X | | | NA | |
| BioTransplant | X | | | NA | |
| Biovail | X | | | NA | |
| Calypte Biomedical | X | | | NA | |
| Catalytica Energy Systems | X | | | NA | |
| Celgene | X | | | NA | |
| Cor Therapeutics | X | | | NA | |
| Corixa | X | | | NA | |
| Cubist Pharmaceuticals | X | | | NA | |
| Curis | X | | | NA | |
| CV Therapeutics | X | | | NA | |
| Cytc | X | | | NA | |
| Digene | X | | | NA | |
| Dyax | X | | | NA | |
| Emisphere Technologies | X | | | NA | |
| Endocardial Solutions (Restricted) | X | | | NA | |
| Envirogen | X | | | NA | |
| EP Med Systems | X | | | NA | |
| Exelixis | X | | | NA | |
| Focal | X | | | NA | |
| Genzyme | X | | | NA | |
| Genzyme Biosurgery | X | | | NA | |
| Gilead Sciences | X | | | NA | |
| IDEXX Laboratories | X | | | NA | |
| ImClone Systems | X | | | NA | |
| Interpore Cross | X | | | NA | |

Edgar Filing: H&Q HEALTHCARE INVESTORS - Form 13F-HR

| | | |
|--------------------------------|---|----|
| KeraVision | X | NA |
| Landec | X | NA |
| Lynx Therapeutics | X | NA |
| Martek Biosciences | X | NA |
| MedImmune | X | NA |
| Molecular Devices | X | NA |
| Orthovita (Restricted) | X | NA |
| Quintiles Transnational | X | NA |
| Radiance Medical Systems | X | NA |
| Scios | X | NA |
| Sepracor | X | NA |
| Telik | X | NA |
| Teva Pharmaceutical Industries | X | NA |
| Transkaryotic Therapies | X | NA |
| Tularik | X | NA |
| Verdant Brands | X | NA |
| Versicor | X | NA |
| Versicor (Restricted) | X | NA |

COLUMN TOTALS